Vikas Dandekar

Health News: For Vijay Patil, a cancer specialist at Mumbai’s PD Hinduja Hospital, it was another painful day. A 72-year-old patient from Dahanu, a city suburb, ha.

Indian drug maker Zydus Lifesciences is close to acquiring a US company. The deal is expected to be between $100 to $150 million. This acquisition will help Zydus build its own distribution network for anti-cancer drugs in the US. The target company also has its own pipeline of biologic drugs. A deal is anticipated soon.

Pfizer is focusing on India for future growth. The company plans to launch new medicines quickly and at affordable prices. India is seen as a crucial market for new treatments in cancer, obesity, and vaccines. Pfizer is also working on local clinical studies for future drug launches.

A new gene editing medicine, VERVE-102, offers hope for millions with heart conditions. Eli Lilly's drug showed significant reductions in bad cholesterol. This one-time infusion could transform heart disease management. Larger trials are planned, with a Phase II trial starting soon. This approach may eventually benefit broader populations at high cardiovascular risk.

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to broaden its footprint in North America and Europe through sophisticated product offerings, Cipla is also intensifying its focus on managing chronic conditions such as diabetes and heart diseases in India.

Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant global product filings over the next three years. Cipla will also expand its presence in North America and Europe. Innovation is expected to contribute a meaningful portion of revenues in the coming decade.

Wockhardts newly approved antibiotic Zaynich has the potential to transform the treatment of drug-resistant infections, according to Mahesh Patel, the scientist behind the drug. Approved by the US FDA for complicated urinary tract infections, Zaynich combines cefepime and zidebactam, using a novel “beta-lactam enhancer” mechanism that blocks two key steps in bacterial cell-wall synthesis, helping it overcome virtually all known resistance mechanisms.

It targets superbugs that resist current treatments. Zaynich offers a powerful synergy to overcome resistance. The drug has a significant market opportunity. Wockhardt anticipates market exclusivity until around 2038.

Wockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected to generate $1.5-2 billion in peak annual sales within 4-6 years. Wockhardt aims for a 20% share of the AMR market. The company is also developing new antibiotics for its pipeline.

Wockhardt Hospitals has received US approval for Zaynich, an innovative antibiotic expected to achieve peak sales of $1.5-2 billion annually in the next 4-6 years. CEO Habil Khorakiwala outlines the company's strategy and market projections.